Abstract
Affan Shoukat, Thomas N. Vilches, Seyed M. Moghadas, Pratha Sah, Eric C. Schneider, Jaimie Shaff, Alexandra Ternier, Alison P. Galvani
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States
2021
Unresolved referenced work
Kept as external metadata until matched
Can the USA return to pre-COVID-19 normal by July 4?
10.1016/s1473-3099(21)00324-8 · 2021
Social contacts and mixing patterns relevant to the spread of infectious diseases
10.1371/journal.pmed.0050074 · 2008
Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK
10.1186/s12916-020-01597-8 · 2020
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
10.1126/science.abg3055 · 2021
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
10.1038/s41586-021-03426-1 · 2021
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
10.1136/bmj.n579 · 2021
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
10.1126/science.abh2644 · 2021
Unresolved referenced work
Kept as external metadata until matched
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
10.1001/jamainternmed.2020.7976 · 2021
Unresolved referenced work
2021
Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing
10.1126/science.abb6936 · 2020
The implications of silent transmission for the control of COVID-19 outbreaks
10.1073/pnas.2008373117 · 2020
Infectivity of asymptomatic versus symptomatic COVID-19
10.1016/s0140-6736(20)32651-9 · 2021
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
10.1016/j.cell.2021.02.037 · 2021
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
10.1038/s41591-021-01318-5 · 2021
Coronavirus variants are spreading in India - what scientists know so far
10.1038/d41586-021-01274-7 · 2021
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
2021
Unresolved referenced work
2021
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
10.1016/s2666-5247(21)00068-9 · 2021
Projecting demand for critical care beds during COVID-19 outbreaks in Canada
10.1503/cmaj.200457 · 2020
Projecting hospital utilization during the COVID-19 outbreaks in the United States
10.1073/pnas.2004064117 · 2020
Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020
10.15585/mmwr.mm6915e3 · 2020
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020
10.15585/mmwr.mm6913e2 · 2020
Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis
10.1136/bmj.n1412 · 2021
A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York
2021
Unresolved referenced work
Kept as external metadata until matched
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
10.1056/nejmoa2028436 · 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
10.1056/nejmoa2034577 · 2020
Evaluation of COVID-19 vaccination strategies with a delayed second dose
10.1371/journal.pbio.3001211 · 2021
Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants
10.1016/j.eclinm.2021.100865 · 2021
National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
10.1056/nejmc2104974 · 2021
Unresolved referenced work
2021
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
10.1056/nejmoa2101765 · 2021
Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States
10.1126/scitranslmed.abh3826 · doi-reference
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
10.1056/nejmoa2035389 · doi-reference
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
10.1056/nejmoa2101544 · doi-reference
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021
10.15585/mmwr.mm7018e1 · doi-reference
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study
10.1016/s1473-3099(21)00330-3 · doi-reference
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
10.1016/s0140-6736(21)00947-8 · doi-reference